impact factor
logo
 

Full Papers

 

Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

 

  1. Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain.
  2. Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  3. Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  4. Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  5. Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain.
  6. Central Laboratory Division. Hospital Universitario de Canarias, Tenerife, Spain.
  7. Central Laboratory Division. Hospital Universitario de Canarias, Tenerife, Spain.
  8. Division of Internal Medicine, Hospital Universitario Marqués de Valdecilla-IDIVAL, Universidad de Cantabria, RETICEF, Santander, Spain.
  9. Division of Internal Medicine, Hospital Universitario Marqués de Valdecilla-IDIVAL, Universidad de Cantabria, RETICEF, Santander, Spain.
  10. Division of Epidemiology and Computational Biology, School of Medicine, IDIVAL, University of Cantabria, Santander; and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain.
  11. Dept.Rheumatology, Complejo Hosp.Univ. Santiago de Compostela, Spain; School of Medicine, Univ.Cantabria, Santander, Spain; Cardiovascular Pathophysiology & Genomics Res.Unit, School Physiology, Health Sciences, Univ. Witwatersran, Johannesburg, S.Africa.

CER9274
2016 Vol.34, N°6
PI 1013, PF 1019
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 27606890 [PubMed]

Received: 20/01/2016
Accepted : 19/04/2016
In Press: 31/08/2016
Published: 28/11/2016

Abstract

OBJECTIVES:
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation and that has been linked with cardiovascular risk. The purpose of the present study was to examine whether PCSK9 levels are related to both abnormalities in the lipid profile and the severe atherosclerosis that occur in rheumatoid arthritis (RA) patients.
METHODS:
Cross-sectional study that encompassed 520 individuals; 326 patients with RA and 194 age- and sex-matched controls. PCSK9 and lipoproteins serum concentrations, standard lipid profile and carotid intima-media thickness (cIMT) and carotid plaques were assessed in patients and controls. A multivariable analysis, adjusted for standard cardiovascular risk factors, was performed to evaluate the influence of PCSK9 on RA related dyslipidaemia and subclinical carotid atherosclerosis.
RESULTS:
After adjusting for classical cardiovascular risk factors, lipid profile and statins, RA patients showed lower PCSK9 serum concentrations than controls (beta coefficient -45 95%CI [-53, -38] ng/ml, p=0.00). PCSK9 was associated with both cIMT and the presence of carotid plaques in RA patients. However, this association was lost after adjusting for classical cardiovascular risk factors.
CONCLUSIONS:
PCSK9 is down-regulated in patients with RA.

Rheumatology Article